# Bioequivalence Study of Two Formulations of Lisinopril Tablet 20 mg in Healthy Volunteers Under Fasting Conditions

> **NCT05061901** · PHASE1 · COMPLETED · sponsor: **Pharmtechnology LLC** · enrollment: 38 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Lisinopril tablet 20 mg
- **DRUG:** Zestril® tablet 20 mg

## Key facts

- **NCT ID:** NCT05061901
- **Lead sponsor:** Pharmtechnology LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-06
- **Primary completion:** 2021-11-06
- **Final completion:** 2021-11-06
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2022-07-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05061901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05061901, "Bioequivalence Study of Two Formulations of Lisinopril Tablet 20 mg in Healthy Volunteers Under Fasting Conditions". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05061901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*